Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice - PubMed (original) (raw)
. 2008 Aug 1;32(6):1549-56.
doi: 10.1016/j.pnpbp.2008.05.020. Epub 2008 Jun 25.
Affiliations
- PMID: 18579278
- DOI: 10.1016/j.pnpbp.2008.05.020
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice
Angelo O Rosa et al. Prog Neuropsychopharmacol Biol Psychiatry. 2008.
Abstract
Glycogen synthase kinase-3beta (GSK-3beta) is an enzyme that phosphorylates glycogen synthase, thereby inhibiting glycogen synthesis. Besides this role, it is now believed that this enzyme plays an important role in the pathophysiology of many brain diseases including depression. Some inhibitors of this enzyme have shown antidepressant effects in animal models. This study investigated the effects of a novel thiadiazolidinone NP031115, a putative GSK-3beta inhibitor, and the well-established GSK-3beta inhibitor AR-A014418 in the mouse forced swimming test (FST), a model widely used to evaluate antidepressant activity. We found that NP031115 had an IC50 of 1.23 and 6.5 microM for GSK-3beta and GSK-3alpha, respectively. NP031115 (0.5 and 5 mg/kg, i.p.), in a way similar to imipramine (15 mg/kg, i.p), fluoxetine (32 mg/kg, i.p), AR-A014418 (9 mg/kg, i.p.), and rosiglitazone (5 microg/site, i.c.v.), significantly reduced immobility time in the FST. NP031115 at the higher dose and AR-A014418 (9 mg/kg, i.p.) reduced locomotion in the open-field test. Rosiglitazone (30 microM), AR-A014418 (1 microM), PG(J2) (10 microM), and NP031115 (1, 10 and 25 microM) activate PPARgamma in CHO transfected cells. GW-9662 (10 microg/site, i.c.v, a PPARgamma antagonist) administered 15 min before NP03115 (5 mg/kg, i.p.) or co-administered with rosiglitazone (5 microg/site, i.c.v.) prevented the antidepressant-like effect of these drugs in the FST. The results of this study show that NP031115 can exhibit an antidepressant effect, likely by inhibiting GSK-3beta and enhancing PPARgamma activity.
Similar articles
- Involvement of PI3K, GSK-3β and PPARγ in the antidepressant-like effect of folic acid in the forced swimming test in mice.
Budni J, Lobato KR, Binfaré RW, Freitas AE, Costa AP, Martín-de-Saavedra MD, Leal RB, Lopez MG, Rodrigues AL. Budni J, et al. J Psychopharmacol. 2012 May;26(5):714-23. doi: 10.1177/0269881111424456. Epub 2011 Oct 30. J Psychopharmacol. 2012. PMID: 22037925 - AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test.
Gould TD, Einat H, Bhat R, Manji HK. Gould TD, et al. Int J Neuropsychopharmacol. 2004 Dec;7(4):387-90. doi: 10.1017/S1461145704004535. Epub 2004 Jul 26. Int J Neuropsychopharmacol. 2004. PMID: 15315719 - Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors.
Rosa AO, Egea J, Martínez A, García AG, López MG. Rosa AO, et al. Exp Neurol. 2008 Jul;212(1):93-9. doi: 10.1016/j.expneurol.2008.03.008. Epub 2008 Mar 25. Exp Neurol. 2008. PMID: 18471812 - The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Costemale-Lacoste JF, Guilloux JP, Gaillard R. Costemale-Lacoste JF, et al. Encephale. 2016 Apr;42(2):156-64. doi: 10.1016/j.encep.2016.02.003. Epub 2016 Mar 16. Encephale. 2016. PMID: 26995153 Review. - Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders.
Gould TD, Picchini AM, Einat H, Manji HK. Gould TD, et al. Curr Drug Targets. 2006 Nov;7(11):1399-409. doi: 10.2174/1389450110607011399. Curr Drug Targets. 2006. PMID: 17100580 Review.
Cited by
- Identification and characterization of small molecule antagonists of pRb inactivation by viral oncoproteins.
Fera D, Schultz DC, Hodawadekar S, Reichman M, Donover PS, Melvin J, Troutman S, Kissil JL, Huryn DM, Marmorstein R. Fera D, et al. Chem Biol. 2012 Apr 20;19(4):518-28. doi: 10.1016/j.chembiol.2012.03.007. Chem Biol. 2012. PMID: 22520758 Free PMC article. - The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.
Griebel G, Stemmelin J, Lopez-Grancha M, Boulay D, Boquet G, Slowinski F, Pichat P, Beeské S, Tanaka S, Mori A, Fujimura M, Eguchi J. Griebel G, et al. Sci Rep. 2019 Dec 2;9(1):18045. doi: 10.1038/s41598-019-54557-5. Sci Rep. 2019. PMID: 31792284 Free PMC article. - Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.
Chiu CT, Chuang DM. Chiu CT, et al. Pharmacol Ther. 2010 Nov;128(2):281-304. doi: 10.1016/j.pharmthera.2010.07.006. Epub 2010 Aug 10. Pharmacol Ther. 2010. PMID: 20705090 Free PMC article. Review. - A new avenue for lithium: intervention in traumatic brain injury.
Leeds PR, Yu F, Wang Z, Chiu CT, Zhang Y, Leng Y, Linares GR, Chuang DM. Leeds PR, et al. ACS Chem Neurosci. 2014 Jun 18;5(6):422-33. doi: 10.1021/cn500040g. Epub 2014 Apr 11. ACS Chem Neurosci. 2014. PMID: 24697257 Free PMC article. Review. - Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.
Millan MJ. Millan MJ. Neurotherapeutics. 2009 Jan;6(1):53-77. doi: 10.1016/j.nurt.2008.10.039. Neurotherapeutics. 2009. PMID: 19110199 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous